Analyzing cancer treatment outcomes using a new statistical method
Official title: Survival Data Analysis using general censoring-free incident rate
Funded at Dana-Farber Cancer Inst · NIH-11036324 · Data updated 2026-11-12
This study is testing a new way to better understand how cancer treatments work, so patients and doctors can make smarter choices about care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | March 1, 2024 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $334,596 |
| NIH project number | 5R01GM152499-02 |
| Project ID | NIH-11036324 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include cancer patients who are considering or currently undergoing treatment and are seeking detailed information about the risks and benefits of their options.
✕Less likely to help
Patients who are not currently undergoing cancer treatment or those with conditions unrelated to cancer may not benefit from this research.
What this research studies
This research focuses on improving how we analyze the effectiveness of cancer treatments by developing a new statistical method that provides clearer insights into treatment risks and benefits. Traditionally, methods like the log-rank test have been used, but they often lack the detailed information needed for patients and clinicians to make informed decisions. The new approach, called the average hazard, offers a more interpretable measure of treatment effects over time, which could help guide patient-centered treatment choices. By utilizing this innovative method, the research aims to enhance the understanding of how different cancer therapies impact patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more informed treatment decisions for cancer patients, improving their overall care and outcomes.
How similar studies have gone: While traditional methods have been widely used, this new approach represents a novel advancement in cancer treatment analysis, aiming to fill gaps left by previous methodologies.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Uno, Hajime — Dana-Farber Cancer Inst
- Study coordinator: Uno, Hajime
Related research
Other NIH-funded projects on the same topics.
-
Helping young people with cancer understand their genetic risks
This study is creating a special program to help teenagers and young adults with hereditary cancer risks learn about their health and make smart choices, while also supporting their families along the way.
-
Core administrative hub for a multifaceted cancer center program
A large, international cancer research program at Dana-Farber aims to advance a curative strategy for multiple myeloma by coordinating translational research, clinical trials, and data analysis.
-
Automated, interactive lab tool to define radiation targets in cancer care
Aims to make it easier and safer to outline the area to treat in radiation therapy for cancers by using smart software and a patient-friendly interface.
-
Cancer Atlas Network data hub to share big cancer data
A national project helps researchers store, harmonize, and share large cancer data collections so doctors and scientists can learn from many patients.
-
Bridge-building cancer research partnership for education, outreach, and science
A joint effort between UMass Boston and Harvard Cancer Consortium to accelerate cancer research and education by connecting lower-resourced institutions with a leading cancer center.
-
NexTGen: Next-Generation T cell therapy for childhood cancers
A charity-friendly overview: researchers at Dana-Farber are developing advanced engineered T-cell therapies to treat pediatric solid cancers like brain tumors and sarcomas.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.